Table 4.
Clinical trials with molecular targeting agents coupled with PD-1/PD-L1 inhibitors (http://clinicaltrials.gov/, accessed on 1 June 2021).
| Agent | Target | Combination | Phase | Reference |
|---|---|---|---|---|
| Anlotinib (AK105) | Multi-kinase | Anti-PD-1 | I/II | NCT04803851 |
| Defactinib | FAK | Pembrolizumab | I/II | NCT02758587 |
| LYT-200 | Galectin-9 | Anti PD-1 | I/II | NCT04666688 |
| Anetumab Ravtansine | Mesothelin | Nivolumab Nivolumab/Ipilimumab Nivolumab/gemcitabine |
I/II | NCT03816358 |
| Anlotinib | Multi-kinase | Toripalimab | I/II | NCT04718701 |
| Olaptesed pegol (NOX-A12) | CXCL12 | Pembrolizumab | I/II | NCT03168139 |
| Entinostat | HDAC | Nivolumab | II | NCT03250273 |
| Galunisertib | TGFβRI | Durvalumab | I | NCT02734160 |
| Merestinib | MET | LY3300054 | I | NCT02791334 |
| Pexidartinib | CSF1R | Durvalumab | I | NCT02777710 |
| Danvatirsen | STAT3 | Durvalumab | II | NCT02983578 |
| Plerixafor | Hematopoietic stem cells | Cemiplimab | II | NCT04177810 |
| KY1044 | ICOS | Atezolizumab | I/II | NCT03829501 |
| Ibrutinib | BTK | Durvalumab | I/II | NCT02403271 |
| Defactinib | FAK | Pembrolizumab | II | NCT03727880 |
| Itacitinib | JAK1 | Pembrolizumab | I | NCT02646748 |